SEC Form 4 · accession 0001159036-26-000082
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mahesh Krishnan
Director
Period of report
Jun 29, 2026
Accepted (ET)
Jun 30, 2026 · 5:25 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 29, 2026 | M | 7,304 | $38.46 | A | 21,766 | D | |
| Common Stock | Jun 29, 2026 | S | 7,304 | $75.00 | D | 14,462 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2 | $38.46 | Jun 29, 2026 | M | 7,304 | D | — | Apr 25, 2034 | Common Stock | 7,304 | 1,500 | D |
Explanation of responses
- F1The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 19, 2026 in accordance with Rule 10b5-1.
- F2Grant to Reporting Person of options exercisable as of April 25, 2025.